Europe Needle-Free Injection Systems Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Fillable Needle-free Injectors and Prefilled Needle-free Injectors), Technology (Jet-Based Needle-free Injectors, Spring-Based Needle-free I

Europe Needle-Free Injection Systems Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Fillable Needle-free Injectors and Prefilled Needle-free Injectors), Technology (Jet-Based Needle-free Injectors, Spring-Based Needle-free Injectors, Microarray Patch Injectors, and Others), Type (Liquid-Based Needle-free Injectors, Projectile-based Needle-free Injectors, and Powder-Based Needle-free Injectors), Usability (Disposable and Reusable), Site of Delivery (Subcutaneous Injectors, Intramuscular Injectors, and Intradermal Injectors), Application (Vaccine Delivery, Insulin Delivery, Oncology, Pain Management, Dermatology, and Others), and End User (Hospitals, Home Care Settings, Research Laboratories, Pharmaceutical & Biotechnological Companies, and Other End User)

The Europe needle-free injection systems market is expected to grow from US$ 43.78 million in 2022 to US$ 114.76 million by 2028; it is estimated to grow at a CAGR of 17.4% from 2022 to 2028.

Rising Demand for Vaccines and Biosimilars to Fuel Europe Needle-Free Injection Systems Market

The use of biosimilars is increasing in the treatment of various ailments such as cancer, hepatitis, diabetes, and several other acute and chronic diseases. With the rising prevalence of these illnesses, the need for biosimilars is also increasing, which is presenting a huge opportunity for pharmaceutical & MedTech manufacturers to develop innovative delivery solutions for biosimilars. As several biosimilars and vaccines are administered through injections, the use of needle-free injection technology can provide an easy-to-use and safe method for administering biosimilars without a traditional injection apparatus or skilled staff. Further, many biopharmaceutical manufacturers, vaccine companies, and needle-free device manufacturers are entering into strategic acquisitions and collaborations to leverage the growth potential in the vaccine market. Therefore, the launch of effective and safe drug delivery devices using needle-free injection technology may boost the market growth in the coming years. For instance, in January 2019, Enesi Pharma and Geovax collaborated on multiple vaccines administered using Implavax needle-free injection devices. Also, in August 2021, PharmaJet partnered with Zydus Cadila for the world’s first plasmid DNA COVID-19 vaccine delivery via needle-free injection. In addition, the company also partnered with Abnova to produce and supply the COVID-19 mRNA vaccine using needle-free injection technology. Many patients have a phobia for needles, which has led to the low demand for injectable devices; as a result, many companies are now aiming to develop needle-free injectors with effective and painless solutions. Thus, all these factors encouraging the ease-to-use benefit of these injectors will provide more opportunities for the companies to develop innovative products, which is expected to boost the growth of the Europe needle-free injection systems market during the forecast period.

Europe Needle-Free Injection Systems Market Overview

The Europe needle-free injection systems market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Countries such as France and Germany are expected to be the most significant contributors to the needle-free injection system market due to needlestick injuries and diabetes in the region. International Diabetes Federation (IDF) estimated that diabetes prevalence (9.2%) and the number of people with diabetes (61 million) in Europe will increase by 13% by 2045. Sharps injuries, particularly needlestick injuries, increase the risk of potentially life-threatening infections. Every year in Europe, approximately 1.2 million needlestick injuries are suffered by healthcare staff. More than 30 dangerous blood-borne pathogens are transmitted by contaminated needles, including hepatitis B, hepatitis C, and HIV.

Further, Germany is one of the key economies of the European region in terms of revenue generation and future opportunities for the needle-free injection system market. The increasing need for self-administration of drugs in the case of diseases such as diabetes has enhanced the size of the needle-free drug delivery devices industry in Germany. Further, as the prevalence of asthma and other diseases increases across Germany, the demand for inhalers is also expected to rise, which, in turn, drives the needle-free injection system market growth.

Europe Needle-Free Injection Systems Market Revenue and Forecast to 2028 (US$ Million)

Europe Needle-Free Injection Systems Market Segmentation

The Europe needle-free injection systems market is segmented on the basis of product, technology, type, durability, and country. Based on product, the Europe needle-free injection systems market is bifurcated into fillable needle-free injectors and prefilled needle-free injectors. The fillable needle-free injectors segment held a larger share of the market in 2022.

Based on technology, the Europe needle-free injection systems market is segmented into jet-based needle-free injectors, spring-based needle-free injectors, microarray patch injectors, and others. The jet-based needle-free injectors segment registered the largest share of the market in 2022.

Based on type, the Europe needle-free injection systems market is segmented into liquid-based needle-free injectors, projectile-based needle-free injectors, and powder-based needle-free injectors. The liquid-based needle-free injectors segment registered the largest share of the market in 2022.

Based on durability, the Europe needle-free injection systems market is bifurcated into disposable and reusable. The reusable segment held a larger share of the market in 2022.

Based on site of delivery, the Europe needle-free injection systems market is segmented into subcutaneous injectors, intramuscular injectors, and intradermal injectors. The subcutaneous injectors segment held the largest share of the market in 2022.

Based on application, the Europe needle-free injection systems market is segmented into vaccine delivery, insulin delivery, oncology, pain management, dermatology, and others. The vaccine delivery segment held the largest share of the market in 2022.

Based on end user, the Europe needle-free injection systems market is segmented into hospitals, home care settings, research laboratories, pharmaceutical and biotechnology companies, and others. The hospitals segment held the largest share of the market in 2022.

Based on country, the Europe needle-free injection systems market is segmented into Germany, France, Italy, Spain, the UK, and the Rest of Europe. Germany dominated the market in 2022.

Aijex Pharma International Inc., Crossject, Ferring B.V., Medical International Technologies (MIT Canada) Inc., NuGen Medical Devices, and Zealand Pharma A/S are the leading companies operating in the Europe needle-free injection systems market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe needle-free injection systems market
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Europe needle-free injection systems market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the needle-free injection systems market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution